Withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis

GREEN KIM1,2, TAE-HYOUN KIM3, EUN-HA HWANG1,2, KYU-TAE CHANG2, JUNG JOO HONG2 and JONG-HWAN PARK1

1Laboratory Animal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju 61186; 2National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju, Chungcheongbuk 28116, Republic of Korea; 3Department of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, Rochester, NY 14642, USA

Received October 5, 2016; Accepted March 3, 2017

DOI: 10.3892/ol.2017.6169

Abstract. Human gastric adenocarcinoma (AGS) is one of the most common types of malignant tumor and the third-leading cause of tumor-associated mortality worldwide. Withaferin A (WA), a steroidal lactone derived from Withania somnifera, exhibits antitumor activity in a variety of cancer models. However, to the best of our knowledge, the direct effect of WA on AGS cells has not previously been determined. The present study investigated the effects of WA on the proliferation and metastatic activity of AGS cells. WA exerted a dose-dependent cytotoxic effect on AGS cells. The effect was associated with cell cycle arrest at the G2/M phase and the expression of apoptotic proteins. Additionally, WA treatment resulted in a decrease in the migration and invasion ability of the AGS cells, as demonstrated using a wound healing assay and a Boyden chamber assay. These results indicate that WA directly inhibits the proliferation and metastatic activity of gastric cancer cells, and suggest that WA may be developed as a drug for the treatment of gastric cancer.

Introduction

Human gastric adenocarcinoma (AGS), one of the most common types of malignant neoplasm, is derived from the glandular epithelium of the gastric mucosa (1,2). Although chemotherapy is the primary treatment for gastric cancer, the toxic side effects and low efficacy of existing chemotherapeutic drugs remain a matter of concern (3). Therefore, studies to identify other potential anticancer agents and novel therapeutic approaches, including natural compounds, are important (4). For example, the plants used in traditional medicine are comparatively safe and cost-effective; their potential as alternatives to existing chemotherapeutic drugs should be investigated.

Withania somnifera (winter cherry) and active constituents derived from this plant have been used extensively in the traditional medicine of south Asia (5). Withaferin A (WA), a bioactive withanolide compound isolated from this plant, possibly contributes to the therapeutic effects of W. somnifera, particularly against cancer (6). Indeed, WA has been demonstrated to produce antitumorogenic effects in multiple cancer cell lines, including breast, prostate and lung cancer cells (7-9). Senthil et al (10) recently reported that an extract from W. somnifera inhibits the proliferation of AGS cells by inducing apoptosis and cell cycle arrest. Furthermore, we have recently reported that WA efficiently decreased pro-inflammatory processes in gastric epithelial cells, as well as immune cells, in response to Helicobacter pylori (11,12), which serves a pivotal role in the high incidence of gastric cancer (2). However, a complete understanding of the antitumor effects of WA in gastric cancer remains to be achieved. Therefore, in the present study, the cell proliferation, apoptosis, cell cycle regulation and migration/invasion in AGS cells in response to WA treatment were examined, and the potential therapeutic effects of WA in AGS were further characterized.

Materials and methods

Cell culture and WA. AGS human gastric epithelial cells were purchased from the Korean Cell Line Bank (Seoul, Korea) and cultured with RPMI medium (Welgene, Inc., Daegu, Korea) containing 10% fetal bovine serum (FBS; Corning Incorporated, Corning, NY, USA) and penicillin/streptomycin in a 5% CO2 incubator at 37°C. WA was purchased from...
Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). WA was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA) for use.

**MTT assay.** An MTT assay was performed to determine the cytotoxicity of WA in AGS cells. Cells (1x10^3 cells/well) were seeded in 200 µl complete culture medium (RPMI medium with 10% FBS and penicillin/streptomycin) in 48-well plates and incubated overnight at 37°C. The cells were then incubated with different concentrations of WA (0, 0.5, 1, 2.5 or 5 µM) for 24 h. Each well was washed with PBS twice and then 200 µl MTT (4 mg/ml) was added. Following a 4 h incubation at 37°C, the MTT solution was removed and 200 µl DMSO was added. The plates were agitated for 5 min to dissolve formazan crystals. The optical density (OD) values were determined at 570 nm using an ELISA plate reader (Epoch; BioTek Instruments, Inc., Winooski, VT, USA). Experiments were performed in triplicate with identical conditions.

**Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double-staining assay.** An Annexin V-FITC/PI double-staining assay was performed to analyze cell death in WA-treated AGS cells. Cells were seeded in complete culture medium at a density of 5x10^3 cells/ml into a 60-ml dish and incubated overnight. The cells were incubated with various concentrations of WA (0, 1, 2.5 and 5 µM) for 6 or 18 h at 37°C. The cells were stained using a FITC Annexin V apoptosis detection kit I (BD Pharmingen, San Diego, CA, USA) according to the manufacturer’s protocol and immediately analyzed using flow cytometry (BD FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA). The proportions of cells in four stages, including live, early apoptosis, late apoptosis and necrosis, were calculated using CellQuest™ Pro software (version 5.1; BD Biosciences, San Jose, CA, USA).

**Western blotting.** AGS cells were harvested, washed twice with PBS and lysed in a buffer containing 1% Nonidet-P40 supplemented with protease inhibitors (complete Mini EDTA-free; Roche Applied Science, Mannheim, Germany) and 2 mM dithiothreitol on ice. The extracted protein concentration was determined using a protein assay kit (cat no. 500-0006; Bio-Rad Laboratories, Inc., Hercules, CA, USA). Lysates (30 µg) were separated by 10, 12 and 15% SDS-PAGE and transferred onto nitrocellulose membranes by electroblotting at constant voltage (100 V) for 90 min. The membranes were blocked with 5% skimmed milk at room temperature for 1 h and incubated overnight with primary antibodies against cleaved caspase-3 (1:1,000; cat. no. 9664; rabbit), caspase-7 (1:1,000; cat. no. 8438; rabbit) and caspase-9 (1:1,000; cat. no. 2872; rabbit), cleaved poly (ADP-ribose polymerase) (PARP) (1:1,000; cat. no. 5625; rabbit), cyclin B1 (1:1,000; cat. no. 4138; rabbit) (all Cell Signaling Technology, Inc., Danvers, MA, USA), and β-actin (1:1,000; cat. no. sc130656; rabbit; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Following incubation with secondary horseradish peroxidase-conjugated goat anti-rabbit (1:4,000; cat. no. sc2301; Santa Cruz Biotechnology, Inc.) or goat anti-mouse IgG (1:2,000; cat. no. sc2031; Santa Cruz Biotechnology, Inc.) antibodies for 2 h at room temperature. Proteins were detected with SuperSignal™ West Pico chemiluminescent substrate (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Bands were visualized by exposing the blots onto CP-BU film (Agfa HealthCare NV, Mortsel, Belgium).

**Cell cycle analysis.** To perform cell cycle analysis, AGS cells were seeded in complete culture medium at a density of 5x10^3 cells/ml in 6-well plates and incubated overnight at 37°C. The cells were then treated with 0, 1, 2.5 or 5 µM WA for 12 h at 37°C. Following the incubation, cells were harvested with trypsin and fixed with 50% ethanol overnight at -20°C. The cells were washed with ice-cold PBS and incubated in PBS containing 50 µg/ml PI and 100 µg/ml RNase A solution (both from Sigma-Aldrich; Merck KGaA) for 30 min at 37°C in the dark, followed by flow cytometric analysis (BD FACSCalibur; BD Biosciences). Cell cycle distribution (G1/G0, S and G2/M) was determined using CellQuest™ Pro software.

**In vitro wound healing assay.** An in vitro wound healing assay of AGS cells was performed at various time points, as described previously (13-15). Briefly, cells were plated in 6-well plates and grown to 100% confluency. Following the creation of a wound by scraping with a pipette tip, the cells were washed with PBS, treated with 0, 10, 100 or 500 µM WA in complete culture medium, and subsequently incubated at 37°C for 0, 24, 48 or 56 h. Cells were imaged at each time point with an IX51 widefield microscope (Olympus Corporation, Tokyo, Japan) at x5 magnification with an Orca ER charge-coupled device camera (Hamamatsu Photonics K.K., Hamamatsu, Japan).

**Boyden chamber assay (invasion assay).** The Boyden chamber technique was used to evaluate the invasion activity of AGS cells. The cells were seeded in complete culture medium at a density of 1x10^5 cells/ml in a 60 ml dish, incubated overnight at 37°C and subsequently treated with 0, 1, 2.5 or 5 µM WA for 24 h at 37°C. Briefly, 27 µl RPMI medium containing 10% FBS was added to the lower chambers. A collagen-coated
membrane with 8 µm pores (Neuro Probe, Inc., Gaithersburg, MD, USA) was placed on top of the lower chambers. AGS cells (1.8x10⁶ cells/well) were added to the upper chambers and incubated for 6 h at 37˚C. The cells remaining on the upper side of the membrane were carefully removed using a cotton swab and stained using the Diff-Quick staining kit (Siemens Healthcare GmbH, Erlangen, Germany). The stained cells were counted manually at x100 magnification using a light microscope.

Statistical analysis. All experiments were performed at least in triplicate. Results were expressed as the mean ± standard error of the mean. All statistical analyses (including a paired student's t-test and a one-way analysis of variance with a Bonferroni post hoc test) were performed using GraphPad Prism (version 5.00; GraphPad Software, Inc., La Jolla, CA, USA). P<0.01 was considered to indicate a statistically significant difference.

Results

Treatment with WA results in a dose-dependent inhibition of AGS cell growth. The viability of AGS cells treated with WA was determined using the MTT assay. Cells (1x10⁴ cells/well in a 48-well plate) were exposed to various concentrations (0, 0.5, 1, 2.5, and 5.0 µM) of WA for 24 h. The proportion of viable cells was significantly decreased at the lowest concentration of WA treatment (0.5 µM, P<0.01; Fig. 1). The half-maximal inhibitory concentration of WA in AGS cells at 24 h was 0.75±0.03 µM. At concentrations >1 µM, a more significant decrease in cell viability was observed (P<0.001; Fig. 1). The data indicate that WA exerted a significant inhibitory effect on AGS cell proliferation.

WA inhibits the viability of AGS cells by inducing apoptosis. To determine whether the decreased viability was due to apoptosis in WA-treated AGS cells, an Annexin V-FITC/PI double-staining assay was performed for the identification of early and late apoptotic cells. As demonstrated in Fig. 2A (6 h) and B (18 h), an increase in the frequency of Annexin V-positive cells was observed with increasing concentration of WA (at 6 and 18 h time points), compared with the control (Fig. 2A and B). The rate of apoptosis, including early (Annexin V⁺/PI⁻) and late (Annexin V⁺/PI⁺) stages, for each WA dose was increased compared with untreated cells (Fig. 2A and B). The proportion of early and late apoptotic cells increased in a WA dose-dependent manner (Fig. 2A and B). To understand the apoptotic events in WA-treated AGS cells, cleaved caspase-3, -7 and -9, PARP, Bcl-2, and β-actin were determined by western blotting. WA, withaferin A; AGS, gastric adenocarcinoma; PARP, poly(ADP-ribose) polymerase.

WA leads to G2/M cell cycle arrest in AGS cells. Cell cycle arrest is a key mechanism involved in the induction of cell growth inhibition (16). To test whether WA affects the cell cycle progression of AGS cells, cell cycle distribution analysis was performed with PI staining. AGS cells were treated with 0, 1, 2.5 or 5 µM WA for 12 h. Compared with the negative
control (9.02%), WA treatment resulted in an increase in the proportion of G2/M cells to 43.96, 31.67 and 21.82% in cells treated with 1, 2.5 and 5 µM of WA for 12 h, respectively (Fig. 3A). This phase shift was most marked at lower concentrations of WA treatment. WA-treated cells exhibited lower proportions of G1/G0 cells (33.5% at 1 µM, 38.04% at 2.5 µM and 50.08% at 5 µM) compared with untreated cells (55.05%; Fig. 3A). Similar to the effects on the proportion of cells in G1/G0 phase, WA treatment also resulted in a decrease in the proportion of cells in S phase (Fig. 3A). These results suggest that WA leads specifically to a G2/M phase cell cycle arrest, accounting for the inhibition of proliferation in AGS cells. Moreover, an evident decrease in the expression of Cyclin B1 at 2.5 µM WA treatment for 12 or 24 h was identified (Fig. 3B), which may cause the inhibition of G2/M progression (17). These data suggest that WA has an inhibitory effect on cell cycle progression, thereby resulting in the reduction of proliferation of AGS cells.

WA reduces the migration and invasion activity of AGS cells in vitro. The migratory and invasive abilities of AGS cells treated with WA were evaluated using an in vitro wound healing assay and a Boyden chamber assay. WA treatment tended to inhibit the migration of cells towards the wound at earlier time points (between 24 and 48 h) and the difference compared with the extent of cell migration observed in the untreated cells was statistically significant at 56 h (P<0.01, n=3; Fig. 4A and B). In the Boyden chamber assay, it was identified that AGS cells treated with 1, 2.5 or 5 µM WA exhibited a significant decrease in invasive ability compared with untreated cells at 24 h (Fig. 5A and B), suggesting that WA has an inhibitory effect on the migratory and invasive capabilities of AGS cells.

Discussion

The aim of the present study was to assess the effects of WA on human AGS cells. WA, isolated from W. somnifera, has been ascribed therapeutic properties and its antitumor effects against various types of cancer have been reported (6). Previous studies have demonstrated that WA inhibited the growth of cancer cells, including cutaneous melanoma (18), ovarian cancer (19), prostate cancer (8) and leukemia (4) cells. Multiple molecular mechanisms underlying the antitumor activity of WA have been reported. Reactive oxygen species serve a role in the pro-apoptotic effect of WA in various types of cancer, including leukemia (20) and renal cancer (21). Proteasome inhibition, the induction of endoplasmic reticulum stress, downregulation of Akt serine/threonine kinase phosphorylation and the downregulation of Janus kinase/signal transducer and activator of transcription 3 signaling are also suggested to contribute to cancer cell apoptosis following WA treatment (4,22,23). Transcription factors, including nuclear factor-κB (NF-κB) and mitogen-activated protein kinases, contribute to WA-mediated induction of apoptosis of
leukemia (4,24), glioblastoma (25) and breast cancer (26). The antitumor effects of WA on human AGS were not previously studied, although _W. somnifera_ leaf and root extract have been assessed for their effect on AGS cells (10). In the present study, it was identified that apoptosis was significantly increased in AGS cells treated with WA. As expected, WA treatment of AGS cells upregulated the expression of the initiator (caspase-9) and effector (caspase-3 and -7) caspases, which cleave PARP protein. In addition, WA-treated cells exhibited relatively decreased Bcl-2 levels, which promotes gastric cancer cell survival. Indeed, the downregulation of Bcl-2 has been previously associated with the mechanisms underlying the anti-proliferative effect of WA in a variety of cultured cell types (18,21).

Apoptosis induced by WA may be associated with cell cycle arrest at different phases in cancer cell lines. For example, WA was demonstrated to cause the arrest of cell cycle at the sub-G1 phase in renal carcinoma cells (21), and in the G2/M phase in leukemia (27), uveal melanoma cells (28), breast cancer cells (29) and ovarian carcinoma cells (19). The results of the present study indicated that WA treatment caused G2/M cell cycle arrest in AGS cells, thus delaying the progression of the cells toward mitosis. This G2/M phase shift was more pronounced at lower WA concentrations, whereas apoptotic events were increased at higher WA concentration (Figs. 2 and 3). WA-treated AGS cells also exhibited depleted cyclin B1, which is required to promote G2/M transition (Fig. 3B). The alteration in cyclin B1 has been associated with the induction of cell cycle arrest in the presence of WA; WA was previously demonstrated to decrease the activity of cyclin B1-dependent kinase 1 (Cdk1) and complex formation between cyclin B1 and Cdk1 in cancer cells (30,31). In human breast cancer and ovarian carcinoma cells, WA treatment resulted in the downregulation of cell division cycle 25°C, which activates cyclin B1-Cdk1 complexes (19,31). These data suggest that apoptosis induced by WA may be initiated by G2/M phase cell cycle arrest due to the change in the levels of cyclin B1.

Invasion and metastasis are hallmarks of cancer development. WA has been reported to inhibit the metastatic behavior of human cancer cells (32). In the _in vitro_ setting of the present study, AGS cell migration and invasion were markedly inhibited by WA. Vimentin and matrix metalloproteinases (MMPs) may be potential target molecules for WA in AGS cells, although these were not examined in the present study. Vimentin, the level of which is associated with cell metastasis and motility in patients with gastric cancer (33), was expressed at a high level in the metastatic gastric cancer cell line TMC-1, and at a low level in the non-invasive gastric cancer cell line SC-M1 (34). WA directly binds to the cysteine residues of vimentin to modify the domain structure of vimentin (35), resulting in the impairment of the function of this protein in gastric cancer (33). In addition to vimentin, MMPs are associated with gastric cancer invasion and metastasis, and are used as markers to assess the progression of gastric cancer (36). In gastric cancer cells, MMP-2 and MMP-9 serve important roles in cancer infiltration, and MMP-2 and MMP-9 expression was demonstrated to be associated with the progression of the tumor (37). WA blocks MMP-9 activity in metastatic cancer cell lines (38), suggesting a possible explanation for WA-induced inhibition of metastasis in AGS cells. Further investigation is warranted, however, to clarify the role of vimentin and MMPs in the pharmacological activity of WA in AGS cells.

The inflammatory response is one of the major factors promoting the initiation and progression of gastric cancer (39). In particular, _H. pylori_ infection may induce gastric cancer by enhancing the inflammatory response (40). In addition, upregulation of interleukin 8, vascular endothelial growth factor, angiogenin, urokinase-type plasminogen activator and MMP-9 genes by _H. pylori_ was reported to regulate the metabolism and the invasion of gastric cancer cells (41,42). Recently, our group reported that WA inhibited the activation of NF-xB and pro-inflammatory cytokine production in gastric epithelial and immune cells infected with _H. pylori_ (11,12). Therefore, there is evidence to suggest that the anti-inflammatory effects of WA may hinder the progression of gastric adenocarcinogenesis.

To the best of our knowledge, the results of the present study demonstrate for the first time that WA inhibits human AGS cell growth by the induction of G2/M cell cycle arrest and apoptosis. WA also suppressed AGS cell migration and
invasion. These results provide support for the development of WA as a novel therapeutic strategy against gastric cancer.

Acknowledgements

The present study was supported by the Program for Basic Research in Science and Engineering, funded by the National Research Foundation of Korea in the Ministry of Science, Information and Communications Technology and Future Planning of Korea (grant no. NRF-2015R1A2A2A010002360) and a grant from the Korea Research Institute of Bioscience and Biotechnology (grant no. KGM421642).

References